Development of a PET Prostate-Specific Membrane Antigen Imaging Agent: Preclinical Translation for Future Clinical Application
Technical Report,30 Sep 2017,29 Sep 2018
University of California San Francisco United States
Pagination or Media Count:
The overall objective of this research project is to collect chemistry and preclinical data on two promising new small-molecule peptidomimetic imaging agents labeled with positron emitting fluorine-18. These data will enable the filing of an exploratory IND expIND phase 0 application to the FDA by the end of the funding period. The small molecule imaging agents under study home to prostate specific membrane antigen PSMA that is prevalent on a majority of prostate cancers. The availability of these imaging agents will support diagnosis and staging of prostate cancer without the need for a biopsy as well as provide valuable information to guide therapeutic intervention and monitor the treatment outcome.
- Medicine and Medical Research